Trial Profile

Phase I study of KD 295, an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KD 295 (Primary)
Indications Influenza A virus H5N1 subtype
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK; Kaketsuken

Most Recent Events

30 Oct 2015 New trial record
25 Sep 2015 Results published in Vaccine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com